Immunization; Infection Clinical Trial
Official title:
The Effect of Using Vaccine Reminder and Tracker Bracelets to Improve Routine Childhood Immunization Coverage and Timeliness in Pakistan: a Randomized Control Trial.
Pakistan has one of the highest infant mortality rates in the world in part, due to the low
coverage (54%) for all basic vaccinations. Low uptake, lack of awareness among parents to
complete the recommended immunization schedule and inability to remember vaccine appointments
are some of the key factors hindering improvement in uptake of immunization services. On the
supply side, ineffective methods to track children's' vaccine doses means that there is no
reliable mechanism to verify vaccine administration and estimate accurate immunization
coverage.
This study proposes to develop and test two types of silicon bracelets for children to
stimulate immunization demand and simultaneously address supply side verification issues.
These bracelets use a combination of numbers and symbols to denote the age of the child and
due vaccines and are designed for illiterate or uneducated mothers; are low-cost and
adaptable to most local settings. At the time of vaccine administration, the appropriate
symbol denoting the vaccine on the bracelets is punched and therefore the bracelets can serve
as effective reminders for mothers for timely immunization of their child and as a tool for
vaccinators to verify vaccine administration and coverage.
An individually randomized, three-arm parallel group design randomized control trial will be
conducted with equal allocation in the two treatment groups and control group. Children in
intervention group A will receive the simple silicon bracelets, children in intervention
group B will receive the bracelets developed by Alma Sana Inc. and children in the Control
group will not receive any intervention. The impact of these immunization reminder bracelets
on immunization coverage and timeliness will be evaluated through a randomized control trial
(RCT) across 4 immunization centers in Karachi. To evaluate the bracelets' impact, variables
of interest-coverage and timeliness rates of pentavalent-3/PCV-3/polio-3 and Measles 1
vaccine will be compared between Group A and the Control Group and Group B and the Control
Group.
Proposed results include increase in immunization coverage and timeliness of
Pentavalent-3/Pneumococcal Conjugate Vaccine (PCV-3)/Polio-3 and Measles-1 in the
intervention versus control group.
The study will provide evidence of the bracelet's effectiveness for the global health
community and provide a simple tool for strengthening routine immunization efforts in
Pakistan.
The overall goal of the intervention is improvement in both immunization coverage rates and
timeliness among the study participants through introducing simple silicon bracelets as
childhood vaccination reminders and trackers.
An individually randomized, three-arm parallel group design randomized control trial will be
conducted with equal allocation to evaluate the impact of the Alma Sana bracelet and simple
silicon bracelet by comparing the variables of interest (coverage and timeliness rates of
(pentavalent-3/PCV-3/polio-3 and Measles 1) between treatment groups and the Control Group.
Study Procedures:
A consent form will be used to seek consent from caregivers accompanying the child to screen
the child for the study. Among those who provide consent, a screening form will be used to
identify the eligible participants. After screening, seeking consent from primary caregivers
(mother and/or father) they will be randomized into the treatment groups (to receive the
bracelet) or to serve as a control. The randomization sequence will be created using Stata
version 13 with a 1:1:1 allocation using random block sizes of 3, 6, 9 and 12. The allocation
sequence will be concealed from the study staff responsible for screening and enrolling
participants in serially numbered, opaque, sealed envelopes. After randomization, each child
will be assigned a unique study ID (a sticker containing the study ID will be pasted on the
child's government issued EPI card).
Details of the procedures in the intervention and control groups are outlined below:
Intervention group A and B: Children in both the intervention groups (A and B) will receive
the two different bracelets to be placed on the child's wrist. Additionally, mothers will be
provided instructions explaining the use of the bracelet and helping them decode the symbols
to enable them to use the bracelet to remind themselves of their child's vaccinations.
Children will receive the scheduled EPI vaccine by the vaccinator who will then punch a hole
in the child's bracelet to denote vaccine administration. The child's vaccine data will be
recorded in the EPI card and EPI register as per routine.
All participants (irrespective of whether they are in the treatment group A or B or control
group) will receive the routine EPI vaccinations as per Pakistan's EPI Immunization schedule
(one dose of BCG and polio soon after birth, 3 doses of Pentavalent/Polio/PCV at 6, 10 and 14
weeks, and 2 doses of Measles vaccine and 9 and 15 months of age) and the vaccinator will
record the child's immunization data in the EPI immunization card as well as EPI register.
The difference between the intervention and standard care is only the provision of bracelets
which provide an additional source (apart from the EPI cards) to record and track
vaccinations.
Control group: Children in the control group will receive the scheduled EPI vaccine from the
vaccinator. The child's vaccine data will be recorded in the EPI card and register as per
routine.
Data collection will be done using the following documents over 5 total visits:
1. Enrollment Form: At the child's first visit to the center, the field worker will note
the name and age of the child along with the immunizations received during the visit in
addition to basic demographic information in the enrolment form. This information, along
with basic biographic information is recorded routinely by vaccinators in their
government issued permanent medical registers. An immunization visit typically takes
between 10 and 15 minutes, not including any time spent waiting to be seen by the
vaccinator.
2. Follow-up Form: For the follow up visits by the caregivers to get the subsequent
vaccinations (3 - 4 visits), field workers will be based at the participating EPI
centers throughout the follow-up period. Each follow-up visit takes about 10-15 minutes
of the caregivers time, not including any time spent waiting to be seen by the
vaccinator. Each child in the study is provided a unique EPI number by the EPI staff as
per routine and also a study ID by a field worker. The linkage between the EPI number
and the ID number will be maintained after data collection is complete. The field
workers will use these IDs to identify the study participants when they come for
follow-up visits. At each follow up visit, the field worker will record the vaccine
administered and date for each child in the study, including verifying data on past
immunizations and due vaccines (follow-up form attached). Therefore, for each study
participant, the field workers would collect data 3-4 times during the follow-up period.
The minimum duration of follow up provided to each participant will be until the child
receives Measles-1 vaccine (given at 9 months of age per WHO recommendations). The
maximum duration of follow up provided to each participant will be 11 months.
3. Completion Form: After the completion of follow-up period, short (15-20 minutes) phone
or in-person interviews will be conducted to collect follow up vaccination data (if
missing) and data on experiences of study participants regarding the bracelets
(completion form attached). Phone numbers and addresses are provided as part of the
Enrollment form. It is culturally acceptable for in person interviews to be conducted in
their home. Key data points would include reasons for drop-outs, whether mothers
understood how to use the bracelets, how often mothers said their babies wore the
bracelets and why, what mothers liked and disliked about the bracelets and whether
mothers would continue using the bracelets as reminders moving forward.
Statistical analysis plan:
Intention to treat analysis will be used—that is, all subjects will be analysed with the
assumption that they remained in the treatment group to which they were initially assigned.
Y=c+β1T1+β2T2+γX+ε
Y is the relevant outcome measure (for instance Penta-3 coverage) C is the constant that
gives the value of the outcome for the control group T1 and T2 are treatment dummy variables
for group 1 (Alma Sana bracelets) and group 2 (Simple silicon bracelets) β1 and β2 will
provide the difference in outcome variable between treatment one and the control group and
treatment 2 and the control group respectively X is the set of possible covariates (gender,
mother's education)
Logistic regression will be used to determine whether the difference in outcome between the
two treatment groups and control group are statistically significant and whether the
difference in outcome between the two treatment groups is statistically significant from each
other.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Completed |
NCT04042246 -
Effect of Knowledge on Vaccine Take-up in Adamawa State, Northeastern Nigeria
|
N/A | |
Enrolling by invitation |
NCT05570630 -
VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination
|
N/A | |
Completed |
NCT03145324 -
Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations
|
||
Recruiting |
NCT06185647 -
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
|
||
Recruiting |
NCT05215327 -
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
|
Phase 2 | |
Completed |
NCT03355989 -
Evaluation of Conditional Cash Transfers (CCTs) for Immunization
|
N/A | |
Completed |
NCT02992925 -
Phase 3 Study of BK1310 in Healthy Infants
|
Phase 3 | |
Completed |
NCT03121638 -
Safety Study of NBP608 in Healthy Adult Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
Completed |
NCT05661890 -
Seasonal Influenza and Pneumococcal Vaccination in the Elderly
|
||
Active, not recruiting |
NCT04444518 -
Increasing Influenza and Tdap Vaccination of Pregnant Women
|
N/A | |
Active, not recruiting |
NCT03908164 -
Optimising the Timing of Whooping Cough Immunisation in MUMs
|
Phase 4 | |
Completed |
NCT03379467 -
Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage
|
N/A | |
Not yet recruiting |
NCT03402646 -
Mobile Phone Reminders (and Photovoice) for Routine Immunization in Nigeria - The MOPING Study
|
N/A | |
Completed |
NCT04824638 -
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
|
Phase 2 | |
Recruiting |
NCT05774093 -
Evaluation of COVID-19 Immune Barrier and Reinfection Risk
|
||
Completed |
NCT03083158 -
Immunity to Hepatitis B Vaccine
|
Phase 4 | |
Recruiting |
NCT04816760 -
Immune Cells Phenotypes During COVID-19
|
||
Completed |
NCT04870021 -
Hepatitis B Birth Dose for Newborns
|
Phase 4 |